<!–
–>
Medtronic has reported $7.727bn global revenue for the third quarter (Q3) of fiscal year 2023 (FY23), representing a 4.1% increase on an organic basis.
The organic comparison excludes $26m from the Intersect ENT acquisition as well as a $379m negative impact from foreign currency translation.
For the quarter, which ended on 27 January, the company’s GAAP net income was $1.222bn, representing a 17% decline, while diluted earnings per share (EPS) stood at $0.92, a 16% decline compared to the same quarter of the previous year.
The company’s non-GAAP net income stood at $1.727bn, a 6% decrease, and non-GAAP diluted EPS was $1.30, a 4% decline.
Its US revenue was $4.062bn, representing nearly 52% of the company revenue, which was a 3% increase on a reported basis and 2% increase on an organic basis.
Medtronic reported $2.294bn in non-US developed market revenue, representing a 6% decline on a reported basis and 6% increase on an organic basis.
Its emerging markets revenue stood at $1.371bn, a 1% decline as reported and 5% increase on an organic basis.
The company’s Cardiovascular revenue increased by 1% as reported and 7% on an organic basis, reaching $2.772bn.
The Medical Surgical revenue for the quarter was $2.137bn, representing a 7% decline as reported and 2% decline on an organic basis.
In the Neuroscience portfolio, the company’s revenue stood at $2.248bn, a 5% rise as reported and 7% rise on organic.
Revenue from Diabetes, which decreased by 2% as reported and increased by 3% on an organic basis, was $570m.
Medtronic chairman and CEO Geoff Martha said: “We returned to mid-single digit organic growth as we continue to execute our strategy with urgency.
“Our Cardiovascular and Neuroscience portfolios had strong, high-single-digit organic growth as we launched new products and demonstrated continued strength in our established, market-leading Cardiac Rhythm Management and Spine franchises.
“I’m very encouraged by the rebound in our revenue growth, despite procedure volumes remaining a little softer in a few markets and volume-based procurement in China.”
<!– GPT AdSlot 3 for Ad unit 'Verdict/Verdict_In_Article' ### Size: [[670,220]] —
!– End AdSlot 3 –>
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
- Source: https://www.medicaldevice-network.com/news/medtronic-increase-q3-2023-revenue/
- 2%
- 2023
- a
- acquisition
- Ad
- and
- basis
- ceo
- chairman
- China
- Commons
- company
- Company’s
- compared
- comparison
- continue
- continued
- Creative
- credit
- Currency
- Decline
- decrease
- demonstrated
- Despite
- developed
- Diabetes
- Digit
- Earnings
- emerging
- emerging markets
- encouraged
- established
- execute
- few
- Fiscal
- foreign
- foreign currency
- from
- GAAP
- Global
- GlobalData
- Growth
- HTTPS
- Impact
- in
- Income
- Increase
- increased
- January
- launched
- little
- management
- Market
- market-leading
- Markets
- medical
- nearly
- negative
- net
- Neuroscience
- New
- new products
- organic
- plato
- Plato Data Intelligence
- PlatoData
- portfolio
- portfolios
- previous
- Products
- Q3
- Quarter
- reaching
- rebound
- remaining
- Reported
- Reports
- representing
- revenue
- revenue growth
- Rise
- Said
- same
- Share
- Size
- Strategy
- strength
- strong
- surgical
- The
- Third
- to
- Translation
- unit
- urgency
- us
- volumes
- which
- while
- year
- young
- zephyrnet